JP2018506981A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018506981A5 JP2018506981A5 JP2017544615A JP2017544615A JP2018506981A5 JP 2018506981 A5 JP2018506981 A5 JP 2018506981A5 JP 2017544615 A JP2017544615 A JP 2017544615A JP 2017544615 A JP2017544615 A JP 2017544615A JP 2018506981 A5 JP2018506981 A5 JP 2018506981A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- chain variable
- variable region
- cdrs
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562119793P | 2015-02-23 | 2015-02-23 | |
| US62/119,793 | 2015-02-23 | ||
| US201562241662P | 2015-10-14 | 2015-10-14 | |
| US62/241,662 | 2015-10-14 | ||
| US201662296560P | 2016-02-17 | 2016-02-17 | |
| US62/296,560 | 2016-02-17 | ||
| PCT/US2016/019192 WO2016138038A1 (en) | 2015-02-23 | 2016-02-23 | Anti-dll3 chimeric antigen receptors and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018506981A JP2018506981A (ja) | 2018-03-15 |
| JP2018506981A5 true JP2018506981A5 (enExample) | 2019-04-04 |
Family
ID=56789774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017544615A Pending JP2018506981A (ja) | 2015-02-23 | 2016-02-23 | 抗ｄｌｌ３キメラ抗原受容体および使用方法 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20180044415A1 (enExample) |
| EP (1) | EP3261650A4 (enExample) |
| JP (1) | JP2018506981A (enExample) |
| KR (1) | KR20170120158A (enExample) |
| CN (1) | CN107405362A (enExample) |
| BR (1) | BR112017017927A2 (enExample) |
| CA (1) | CA2977502A1 (enExample) |
| CL (1) | CL2017002150A1 (enExample) |
| CO (1) | CO2017008804A2 (enExample) |
| CR (1) | CR20170436A (enExample) |
| DO (1) | DOP2017000199A (enExample) |
| EA (1) | EA201791884A1 (enExample) |
| EC (1) | ECSP17063327A (enExample) |
| HK (1) | HK1249405A1 (enExample) |
| IL (1) | IL254068A0 (enExample) |
| MA (1) | MA41613A (enExample) |
| MX (1) | MX2017010845A (enExample) |
| PE (1) | PE20171383A1 (enExample) |
| PH (1) | PH12017501521A1 (enExample) |
| SG (1) | SG11201706804SA (enExample) |
| TW (1) | TW201639887A (enExample) |
| WO (1) | WO2016138038A1 (enExample) |
| ZA (1) | ZA201705720B (enExample) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11385233B2 (en) | 2015-03-05 | 2022-07-12 | Autolus Limited | Methods of depleting malignant T-cells |
| US11982673B2 (en) | 2014-03-05 | 2024-05-14 | Autolus Limited | Methods |
| GB201403972D0 (en) | 2014-03-06 | 2014-04-23 | Ucl Business Plc | Chimeric antigen receptor |
| US9708412B2 (en) | 2015-05-21 | 2017-07-18 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
| EP3493844A4 (en) | 2016-05-20 | 2021-03-24 | Harpoon Therapeutics Inc. | SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEIN |
| CN108395482B (zh) | 2017-02-08 | 2021-02-05 | 西比曼生物科技（香港）有限公司 | 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定 |
| AU2018219887B2 (en) | 2017-02-08 | 2024-08-15 | Dragonfly Therapeutics, LLC | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| CN110944661A (zh) | 2017-02-20 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 结合her2、nkg2d和cd16的蛋白质 |
| JP2020530554A (ja) * | 2017-07-20 | 2020-10-22 | シートムエックス セラピューティクス，インコーポレイテッド | 活性化抗体の特性を定性的および／または定量的に分析する方法およびその使用 |
| KR102172092B1 (ko) | 2017-09-19 | 2020-10-30 | 주식회사 엘지화학 | 열가소성 수지 조성물, 이의 제조방법 및 성형품 |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| MX2020003915A (es) | 2017-10-13 | 2020-10-08 | Harpoon Therapeutics Inc | Proteinas trispecificas y metodos de uso. |
| EP3698140A4 (en) * | 2017-10-20 | 2021-07-28 | NantBio, Inc. | BLADDER CANCER IMMUNOTHERAPY SURVEILLANCE METHODS |
| BR112020015994A2 (pt) | 2018-02-08 | 2020-12-15 | Dragonfly Therapeutics, Inc. | Terapia de combinação do câncer que envolve proteínas de ligação multiespecíficas que ativam células natural killer |
| CA3237846A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| CN111989108B (zh) * | 2018-02-13 | 2024-07-16 | 嵌合体生物工程公司 | 利用rna去稳定元件协调基因表达 |
| WO2019164930A1 (en) | 2018-02-20 | 2019-08-29 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use |
| EP3774921A4 (en) * | 2018-04-03 | 2022-01-05 | Dragonfly Therapeutics, Inc. | ANTIBODY VARIABLE DOMAINS AGAINST DLL3 AND USE OF IT |
| JP7479290B2 (ja) * | 2018-04-10 | 2024-05-08 | アムジエン・インコーポレーテツド | Ｄｌｌ３に対するキメラ受容体及びその使用方法 |
| KR20260046525A (ko) | 2018-04-11 | 2026-04-07 | 인히브릭스 바이오사이언스, 인크. | 제한된 cd3 결합을 갖는 다중특이적 폴리펩티드 컨스트럭트 및 관련된 방법 및 용도 |
| CA3097193A1 (en) * | 2018-05-08 | 2019-11-14 | Phanes Therapeutics, Inc. | Anti-dll3 antibodies and uses thereof |
| BR112020023330A2 (pt) | 2018-05-14 | 2021-04-20 | Harpoon Therapeutics, Inc. | porção de ligação para ativação condicional de moléculas de imunoglobulina |
| EP3827019A1 (en) | 2018-07-24 | 2021-06-02 | Inhibrx, Inc. | Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same |
| EP3833392A4 (en) | 2018-08-08 | 2022-05-18 | Dragonfly Therapeutics, Inc. | MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| KR102835308B1 (ko) | 2018-08-08 | 2025-07-21 | 드래곤플라이 쎄라퓨틱스, 인크. | Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질 |
| EP3847254A4 (en) | 2018-09-07 | 2022-08-10 | Beam Therapeutics Inc. | COMPOSITIONS AND METHODS FOR DELIVERING A NUCLEOBASE EDITING SYSTEM |
| WO2020051562A2 (en) | 2018-09-07 | 2020-03-12 | Beam Therapeutics Inc. | Compositions and methods for improving base editing |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| JP7611820B2 (ja) * | 2018-10-11 | 2025-01-10 | インヒブルクス バイオサイエンシズ インコーポレイテッド | Ｄｌｌ３シングルドメイン抗体およびその治療用組成物 |
| US20230158071A1 (en) * | 2018-12-07 | 2023-05-25 | Crage Medical Co., Limited | Tumor combined immunotherapy |
| AU2020215730A1 (en) | 2019-01-31 | 2021-07-29 | Beam Therapeutics Inc. | Nucleobase editors having reduced non-target deamination and assays for characterizing nucleobase editors |
| CN120174005A (zh) | 2019-02-13 | 2025-06-20 | 比姆医疗股份有限公司 | 具有用于修饰靶标序列中核碱基的腺苷脱氨酶碱基编辑器的经修饰的免疫细胞 |
| PH12021551720A1 (en) * | 2019-03-01 | 2022-03-28 | Allogene Therapeutics Inc | Dll3 targeting chimeric antigen receptors and binding agents |
| WO2020182517A1 (en) * | 2019-03-08 | 2020-09-17 | Oncolab Diagnostics Gmbh | Cancer diagnosis and prognosis |
| CN113795262A (zh) * | 2019-04-08 | 2021-12-14 | 东莞凡恩世生物医药有限公司 | 人源化抗dll3嵌合抗原受体及其用途 |
| AU2020275002A1 (en) | 2019-05-14 | 2021-12-23 | Harpoon Therapeutics, Inc. | EpCAM binding proteins and methods of use |
| EP4527466A3 (en) * | 2019-07-17 | 2025-06-18 | Legend Biotech Ireland Limited | Anti-dll3 chimeric antigen receptors and uses thereof |
| JP2022546282A (ja) * | 2019-08-18 | 2022-11-04 | キメラ・バイオエンジニアリング，インコーポレーテッド | Ｇｏｌｄ制御導入遺伝子による併用療法 |
| EP4034138A4 (en) | 2019-09-27 | 2024-07-31 | Beam Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIQUID CANCERS |
| JP7789002B2 (ja) | 2020-01-29 | 2025-12-19 | インヒブルクス バイオサイエンシズ インコーポレイテッド | Ｃｄ２８シングルドメイン抗体ならびにその多価および多重特異性の構築物 |
| US12486331B2 (en) | 2020-01-31 | 2025-12-02 | Gensun Biopharma Inc. | Bispecific T cell engagers |
| US11976133B2 (en) * | 2020-01-31 | 2024-05-07 | Gensun Biopharma Inc. | Bispecific T cell engagers |
| CN115298223A (zh) | 2020-03-12 | 2022-11-04 | 南京传奇生物科技有限公司 | 磷脂酰肌醇蛋白聚糖-2结合部分、嵌合抗原受体及其用途 |
| CN113402612A (zh) | 2020-03-17 | 2021-09-17 | 西比曼生物科技（香港）有限公司 | 靶向cd19和cd20的联合嵌合抗原受体及其应用 |
| CN113444173A (zh) * | 2020-03-25 | 2021-09-28 | 兴盟生物医药(苏州)有限公司 | 金黄色葡萄球菌α-毒素特异性抗体及其应用 |
| JP7512394B2 (ja) | 2020-05-06 | 2024-07-08 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｎｋｇ２ｄ、ｃｄ１６及びｃｌｅｃ１２ａに結合するタンパク質 |
| CA3196831A1 (en) | 2020-09-25 | 2022-03-31 | Beam Therapeutics Inc. | Fratricide resistant modified immune cells and methods of using the same |
| JP2023548590A (ja) * | 2020-11-06 | 2023-11-17 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 小細胞肺がんの分類と治療のための方法およびシステム |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| EP4313081A4 (en) * | 2021-04-02 | 2025-04-09 | Nanjing Legend Biotech Co., Ltd. | MANIPULATED IMMUNE CELLS AND THEIR USES |
| AU2022339815A1 (en) * | 2021-09-02 | 2024-03-14 | Memorial Hospital For Cancer And Allied Diseases | Antigen recognizing receptors targeting dll3 and uses thereof |
| KR20250131823A (ko) | 2023-03-31 | 2025-09-03 | 아벨제타 인크. | Cd20 및 bcma를 표적화하는 이중특이적 키메라 항원 수용체 |
| CN117169518B (zh) * | 2023-11-03 | 2024-01-19 | 赛德特(北京)生物工程有限公司 | T淋巴细胞制剂中的cd3抗体残留物的检测方法和试剂盒 |
| WO2025212519A1 (en) * | 2024-04-01 | 2025-10-09 | Moonlight Bio, Inc. | Dll3 binding proteins and uses thereof |
| WO2026059931A2 (en) * | 2024-09-11 | 2026-03-19 | Telix Targeting Technologies, Inc. | Dll3 antigen binding constructs |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2530091T3 (en) * | 2010-01-29 | 2018-05-28 | Chugai Pharmaceutical Co Ltd | ANTI-DLL3 ANTIBODY |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| BR112014020826A8 (pt) * | 2012-02-24 | 2017-09-19 | Stem Centrx Inc | Anticorpo que se liga especificamente a um epítopo, ácido nucleico, vetor ou célula hospedeira, conjugado de fármaco anticorpo, composição farmacêutica compreendendo o referido anticorpo, uso do mesmo, kit e método de preparação do conjugado |
| EP2863948B1 (en) * | 2012-06-22 | 2018-10-24 | Cytomx Therapeutics Inc. | Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof |
| GB201302447D0 (en) * | 2013-02-12 | 2013-03-27 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
| ES2731681T3 (es) * | 2013-02-22 | 2019-11-18 | Abbvie Stemcentrx Llc | Conjugados de anticuerpo anti-DLL3 y PBD y usos de los mismos |
| WO2016179319A1 (en) * | 2015-05-04 | 2016-11-10 | Cellerant Therapeutics, Inc. | Chimeric antigen receptors with ctla4 signal transduction domains |
-
2016
- 2016-02-22 MA MA041613A patent/MA41613A/fr unknown
- 2016-02-23 CR CR20170436A patent/CR20170436A/es unknown
- 2016-02-23 KR KR1020177026963A patent/KR20170120158A/ko not_active Withdrawn
- 2016-02-23 EA EA201791884A patent/EA201791884A1/ru unknown
- 2016-02-23 WO PCT/US2016/019192 patent/WO2016138038A1/en not_active Ceased
- 2016-02-23 CA CA2977502A patent/CA2977502A1/en not_active Abandoned
- 2016-02-23 TW TW105105289A patent/TW201639887A/zh unknown
- 2016-02-23 PE PE2017001455A patent/PE20171383A1/es unknown
- 2016-02-23 JP JP2017544615A patent/JP2018506981A/ja active Pending
- 2016-02-23 MX MX2017010845A patent/MX2017010845A/es unknown
- 2016-02-23 US US15/553,102 patent/US20180044415A1/en not_active Abandoned
- 2016-02-23 BR BR112017017927A patent/BR112017017927A2/pt not_active IP Right Cessation
- 2016-02-23 CN CN201680019227.8A patent/CN107405362A/zh active Pending
- 2016-02-23 SG SG11201706804SA patent/SG11201706804SA/en unknown
- 2016-02-23 EP EP16756219.8A patent/EP3261650A4/en not_active Withdrawn
- 2016-02-23 HK HK18108019.0A patent/HK1249405A1/zh unknown
-
2017
- 2017-08-20 IL IL254068A patent/IL254068A0/en unknown
- 2017-08-22 ZA ZA2017/05720A patent/ZA201705720B/en unknown
- 2017-08-23 PH PH12017501521A patent/PH12017501521A1/en unknown
- 2017-08-23 CL CL2017002150A patent/CL2017002150A1/es unknown
- 2017-08-23 DO DO2017000199A patent/DOP2017000199A/es unknown
- 2017-08-29 CO CONC2017/0008804A patent/CO2017008804A2/es unknown
- 2017-09-22 EC ECIEPI201763327A patent/ECSP17063327A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018506981A5 (enExample) | ||
| Wei et al. | Current landscape and future directions of bispecific antibodies in cancer immunotherapy | |
| Voss et al. | Molecular design of the Cαβ interface favors specific pairing of introduced TCRαβ in human T cells | |
| JP7233425B2 (ja) | 細胞療法とガンマセクレターゼ阻害剤との組み合わせ | |
| KR102853341B1 (ko) | 조작된 ｔ 세포의 조성물을 제조하는 방법 | |
| JP7299841B2 (ja) | 細胞療法と免疫調節化合物の併用 | |
| Bluhm et al. | CAR T cells with enhanced sensitivity to B cell maturation antigen for the targeting of B cell non-Hodgkin’s lymphoma and multiple myeloma | |
| FI3946621T3 (fi) | Mage a4 -t-solureptoreja | |
| RU2018111462A (ru) | Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток | |
| RU2016143381A (ru) | Способ и композиции для клеточной иммунотерапии | |
| JP2016534717A5 (enExample) | ||
| RU2018107802A (ru) | Полностью человеческие антитела к мезотелину и иммунные эффекторные клетки, нацеленные на мезотелин | |
| RU2018105963A (ru) | Антитело против глипикана-3 и его применение | |
| CN111246862B (zh) | 产生基因工程化细胞组合物的方法和相关组合物 | |
| RU2017100003A (ru) | Улучшенные композиции на основе t-клеток | |
| JP2020515259A5 (enExample) | ||
| RU2015109631A (ru) | Способ и композиции для клеточной иммунотерапии | |
| JP2017527275A5 (enExample) | ||
| JP2015513920A5 (enExample) | ||
| JP2018529327A5 (enExample) | ||
| FI4063397T3 (fi) | Yksidomeenivasta-aineisiin perustuvia antigeenireseptoreita ja menetelmiä niiden käyttämiseksi | |
| FI3708579T3 (fi) | Claudin-6-spesifiset immuunoreseptorit ja t-soluepitoopit | |
| IL268620B2 (en) | Antibodies against LAG3 pharmaceutical formulations containing them, and their uses for cancer treatment | |
| JP2015508757A5 (enExample) | ||
| JP2019513347A5 (enExample) |